Logo
x

Search

Subscribe Now

Merck kgaA

Merck KGaA Reports Results from the P-III (MANEUVER) Study of Pimicotinib for Treating Tenosynovial Giant Cell Tumor (TGCT)

Merck KGaA Reports Results from the P-III (MANEUVER) Study of Pimicotinib for Treating Tenosynovial Giant Cell Tumor (TGCT)

  • November 12, 2024
PharmaShots Weekly Snapshots (May 20 – May 24, 2024)

PharmaShots Weekly Snapshots (May 20 – May 24, 2024)

  • May 24, 2024
Merck KGaA Reports the Acquisition of Mirus Bio, Strengthening Upstream Portfolio

Merck KGaA Reports the Acquisition of Mirus Bio, Strengthening Upstream Portfolio

  • May 23, 2024
Merck KGaA and Inspirna Collaborate for the Development and Commercialization of Ompenaclid (RGX-202) for the Treatment of Colorectal Cancer

Merck KGaA and Inspirna Collaborate for the Development and Commercialization of Ompenaclid (RGX-202) for the Treatment of Colorec...

  • January 5, 2024
Merck KGaA Reports Results for Evobrutinib in P-III Trial for the Treatment of Relapsing Multiple Sclerosis (RMS)

Merck KGaA Reports Results for Evobrutinib in P-III Trial for the Treatment of Relapsing Multiple Sclerosis (RMS)

  • December 6, 2023
Merck KGaA and Hengrui Pharma Entered into a Licensing Agreement to Develop and Commercialize HRS-1167 and SHR-A1904 to Treat Cancer

Merck KGaA and Hengrui Pharma Entered into a Licensing Agreement to Develop and Commercialize HRS-1167 and SHR-A1904 to Treat Canc...

  • October 31, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.